- Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
- Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
- Investigational New Drug application activated and U.S. FDA permission to proceed with Phase II trial to treat complications in COVID-19 patients.
- Phase 1 study in 52 healthy male and female volunteers is complete with LSALT peptide meeting primary endpoint of safety and tolerability.
Press Releases
Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has closed the non-brokered private placement the Company disclosed in a press release June 24, 2020 (The “Offering”).
Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of up to 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $1,000,000 USD (approximately $1,350,000 CAD) (the “Offering”).
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
- International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19
- Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
- Study also recently approved by Health Canada
TORONTO, June 16, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc.
(“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by patients with COVID-19.
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
- International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
- Novel Mechanism of Action – a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
- Study also recently approved in Canada, additional filings made and planned globally
- Phase 1 study in 52 healthy male and female subjects is complete with LSALT peptide meeting primary endpoint of safety and tolerability
Grant of Options
TORONTO, June 11, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that its Board of Directors has granted a total of 1,430,000 stock options to directors, officers and certain consultants pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange (TSXV).
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug Metablok (LSALT peptide) to conduct a Phase II trial to prevent acute organ inflammation and injury experienced by patients with COVID-19.
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
TORONTO, May 19, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has received a No Objection Letter from Health Canada to conduct a Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation experienced by patients with COVID-19.
Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has submitted a Clinical Trial Application to Health Canada for a Phase II human trial for its lead drug Metablok (LSALT peptide) to prevent lung and kidney inflammation in patients with COVID19.